Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11671 Views
-
Last post by NHE
-
- 0 Replies
- 1161 Views
-
Last post by NHE
-
- 0 Replies
- 1937 Views
-
Last post by frodo
-
- 0 Replies
- 1244 Views
-
Last post by frodo
-
- 0 Replies
- 2096 Views
-
Last post by NHE
-
- 0 Replies
- 1695 Views
-
Last post by frodo
-
- 0 Replies
- 1305 Views
-
Last post by NHE
-
- 1 Replies
- 1785 Views
-
Last post by frodo
-
- 0 Replies
- 2490 Views
-
Last post by NHE